AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PDS Biotechnology Set to Release Q2 2025 Earnings: What Investors Need to Know
ByAinvest
Tuesday, Aug 12, 2025 7:41 pm ET1min read
PDS Biotechnology is set to release its quarterly earnings report on August 13. Analysts estimate an EPS of $-0.24. The company has a history of beating EPS estimates, which has led to a 3.05% increase in share price the next day. Long-term shareholders are likely upset given the 60.6% decline in shares over the last 52 weeks.
Title: PDS Biotechnology: Upcoming Earnings Report and Market ExpectationsPDS Biotechnology (PDSB) is poised to release its quarterly earnings report on August 13, 2025. Analysts estimate an earnings per share (EPS) of $-0.24, but the company has a history of beating EPS estimates. In the last quarter, PDS Biotechnology reported an EPS of $-0.21, which was $0.04 higher than the estimated $-0.25 [1].
This past performance has resulted in a 3.05% increase in share price the next day. However, long-term shareholders are likely displeased with the 60.6% decline in shares over the last 52 weeks. The stock has been highly volatile, with significant fluctuations in price. On August 12, 2025, the stock gained 13.89%, rising from $1.08 to $1.23 [2].
Analysts and investors are closely watching the earnings report for both earnings performance and guidance for the next quarter. While earnings performance is crucial, market reactions are often driven by guidance. Historical data suggests that positive guidance can lead to significant price movements.
The stock is currently trading at $1.08, and it is expected to open at $1.18 on August 13, 2025, with a possible trading interval of $1.19 to $1.27. This gives a possible move of 7.12% during the day. The stock is considered a buy candidate due to several short-term positive signals, despite being in a falling trend [2].
References:
1. [1] https://www.benzinga.com/insights/earnings/25/08/47069695/insights-into-pds-biotechnologys-upcoming-earnings
2. [2] https://stockinvest.us/stock/PDSB
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet